FindTrial
Sign In

REGN5678

DRUG4 trials

Sponsors

Regeneron Pharmaceuticals, M.D. Anderson Cancer Center

Conditions

Clear Cell Renal Cell Carcinoma (ccRCC)Metastatic Castration-Resistant Prostate Cancer (mCRPC)Metastatic Castration-resistant Prostate CancerProstate CancerRadical Prostatectomy

Phase 1

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
RecruitingNCT03972657
Regeneron PharmaceuticalsClear Cell Renal Cell Carcinoma (ccRCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Start: 2019-08-12End: 2027-11-15Target: 345Updated: 2026-07-09
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer
RecruitingNCT05125016
Regeneron PharmaceuticalsMetastatic Castration-resistant Prostate Cancer
Start: 2021-11-30End: 2030-03-28Target: 228Updated: 2026-05-05
A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy
RecruitingNCT06085664
M.D. Anderson Cancer CenterProstate Cancer, Radical Prostatectomy
Start: 2023-12-04End: 2028-06-30Target: 42Updated: 2026-08-25
A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC
RecruitingNCT06826768
M.D. Anderson Cancer CenterProstate Cancer
Start: 2025-07-09End: 2029-05-01Target: 60Updated: 2026-08-14

Related Papers

Abstract CT064: Updated safety and efficacy results from a phase 1/2 study of nezastomig, a first-in-class co-stimulatory PSMA×CD28 bispecific antibody (bsAb), plus cemiplimab (anti-PD-1) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Cancer Research2025-04-25
A phase 1/2 study of nezastomig (anti-PSMA×CD28) with or without cemiplimab (anti–PD-1) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and clear cell renal cell carcinoma (ccRCC).
Journal of Clinical Oncology2025-02-101 citations
Phase 1/2 study of REGN4336 alone or in combination with cemiplimab or nezastomig in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology2025-02-101 citations
Preliminary results from a phase 1/2 study of co-stimulatory bispecific PSMAxCD28 antibody REGN5678 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology2023-02-2026 citations
A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer.
Journal of Clinical Oncology2023-02-202 citations
A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer.
Journal of Clinical Oncology2022-06-017 citations
A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti–PD-1) in patients with metastatic castration-resistant prostate cancer.
Journal of Clinical Oncology2021-02-209 citations
A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti-PD-1) in patients with metastatic castration-resistant prostate cancer.
Journal of Clinical Oncology2020-05-205 citations